ADVANCES IN THE MOLECULAR PATHOPHYSIOLOGY, GENETICS AND TREATMENT OF PRIMARY OVARIAN INSUFFICIENCY

Ilpo Huhtaniemi,1 Outi Hovatta,2 Antonio La Marca,3 Gabriel Livera,4 Danielle Monniaux,5 Luca Persani,6* Abdelkader Heddar,7 Katarzyna Jarzabek,8 Triin Laisk-Podar,9,10 Andres Salumets,9,10 Juha S. Tapanainen,11,12 Reiner A. Veitia,13 Jenny A. Visser14 Peter Wieacker,15 Slawomir Wolczynski,16 and Micheline Misrahi,7,*

1) Institute of Reproductive and Developmental Biology, Department of Surgery & Cancer, Imperial College London, Hammersmith Campus, London W12 0NN, UK.
2) Karolinska Institute, Stockholm, Sweden, Nova Southeastern University, Fort Lauderdale, Florida, USA.
3) Mother-Infant Department, University of Modena and Reggio Emilia, Modena 41100, Italy.
4) Laboratory of Development of the Gonads, Unit of Genetic Stability, Stem Cells and Radiation: UMR 967, INSERM; CEA/DRF/iRCM/SCSR; Univ. Paris Diderot, Sorbonne Paris Cité; Univ. Paris-Sud, Université Paris-Saclay. Fontenay aux Roses, F-92265, France.
5) UMR85 PRC, Physiology of Reproduction and Behavior, INRA, CNRS, IFCE, University of Tours, 37380 Nouzilly, France.
6) Department of Clinical Sciences & Community Health, University of Milan, Milan 20122. Division of Endocrine and Metabolic Diseases, Istituto Auxologico Italiano. Milan 20149, Italy.
7) Medical Faculty, Univ. Paris Sud and Paris Saclay, Bicêtre Hospital 94275, Le Kremlin Bicêtre, France.
8) Department of Biology and Pathology of Human Reproduction, Institute of Animal Reproduction and Food Research, Polish Academy of Sciences, 10-748 Olsztyn, Poland.
9) Women’s Clinic, Institute of Clinical Medicine, University of Tartu, L. Puusepa 8, Tartu, Estonia.
10) Competence Centre on Health Technologies, 50410, Estonia.
11) Department of Obstetrics and Gynecology, University of Helsinki and Helsinki University Hospital, Helsinki 00029, Finland.
12) Department of Obstetrics and Gynecology, University Hospital of Oulu, University of Oulu, Medical Research Center Oulu and PEDEGO Research Unit, P.O BOX 23, FI-90029 OYS, Oulu, Finland.

13) Molecular Oncology and Ovarian Pathologies Université Paris-Diderot/Paris 7. Institut Jacques Monod, 15 Rue Hélène Brion, Paris Cedex 13, France.

14) Dept. of Internal Medicine, Erasmus University Medical Center, P.O. Box 2040, 3000 CA Rotterdam, The Netherlands.

15) Institute of Human Genetics. University Hospital of Münster, Vesaliusweg 12-14 D48149 Münster, Germany.

16) Department of Reproduction and Gynecological Endocrinology, Medical University of Bialystok, Sklodowskiej 24A, 15-276 Bialystok, Poland.

*Correspondence: micheline.misrahi@aphp.fr (Micheline Misrahi)
luca.persani@unimi.it (Luca Persani)
Primary ovarian insufficiency (POI) affects ~1% of women before 40 years. The recent leap in genetic knowledge obtained by next-generation sequencing (NGS) together with animal models has further elucidated its molecular pathogenesis, identifying novel genes/pathways. Mutations of >60 genes emphasize high genetic heterogeneity. Genome-wide association studies have revealed a shared genetic background between POI and reproductive aging. NGS will provide a genetic diagnosis leading to genetic/therapeutic counseling: first, defects in meiosis or DNA repair genes may predispose to tumors; second, specific gene defects may predict the risk of rapid loss of a persistent ovarian reserve, an important determinant in fertility preservation. Indeed, a recent innovative treatment of POI by in vitro activation of dormant follicles proved successful.

**KEY WORDS**

Primary ovarian insufficiency, ovary, genetics, meiosis genes, exome, in vitro activation of dormant follicles.

**GLOSSARY**

**Anti-Müllerian hormone (AMH):** a growth factor produced by the granulosa cells of growing follicles. Serum AMH level is an indirect marker of the ovarian reserve and declines with increasing age.

**Follicle-stimulating hormone (FSH):** a pituitary-derived hormone that stimulates estrogen production, follicle growth and selection of the preovulatory follicle. Serum FSH levels are elevated upon ovarian aging due to the loss of negative feedback signals. Normal FSH concentrations (IU/L) are: during follicular phase: 3.5-9.0; ovulatory phase: 7.0-21.5; luteal phase: 1.7-7.0; post-menopause: 26-140.
**Homologous recombination (HR):** a process that assures faithful repair of double strand breaks, one of the most dangerous DNA damages. HR relies on the invasion of a similar DNA matrix (the homologous chromosome during meiosis) as a template to repair the broken DNA. The products of this repair can either be a local replacement of DNA sequence or exchange of large chromosome fragments, respectively termed non-crossover and crossover. The meiotic crossovers are mandatory for proper segregation of chromosomes and thus halving precisely the genome in gametes.

**In vitro activation of small follicles:** Although menstrual cycles cease in POI patients, some of them retain residual dormant ovarian follicles. A new infertility treatment has been developed, which enables POI patients to conceive using their own eggs by activation of the residual dormant follicles by *in vitro* manipulation of signaling pathways responsible for follicular quiescence.

**Luteinizing hormone (LH):** a pituitary-derived hormone that triggers ovulation. Serum LH levels increase upon ovarian aging due to the loss of negative feedback signals.

**Meiosis:** Meiosis is the universal cellular process in eukaryotes that allows forming the haploid reproductive cells.

**Meiotic DNA double strand breaks (DSB):** DSBs are programmed DNA breaks generated early during prophase I and catalyzed by the sporulation 11 homolog (SPO11) enzyme. DSBs are concentrated in “hotspots” designated by PR domain containing 9 (PRDM9) through the deposition of trimethylation on lysine 4 of histone 3.

**Next generation sequencing (NGS)** also known as high-throughput sequencing, describes modern sequencing technologies that allow the sequencing of thousands to millions of DNA molecules simultaneously. It allows sequencing multiple genes and multiple individuals at the same time.

**Non-homologous end joining (NHEJ):** A DSB repair pathway often opposed to HR. NHEJ directly ligates broken DNA ends together. It is believed to result in low repair fidelity in the absence a homologous sequence to guide DNA repair as in HR.

**Ovarian reserve (OR):** a term describing the quality and number of resting oocytes within primordial follicles, and considered as a female’s reproductive potential.

**PI3K/Akt pathway:** the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin (PI3K/Akt/mTOR) signaling pathway regulating various stages of folliculogenesis. Studies in
most genetic mouse models have revealed an essential role of this pathway in primordial follicle activation.

**Primordial germ cells (PGCs):** The primary cells that form the progenitors of gametes. PGCs will populate the embryonic gonads and differentiate into either oocytes or spermatocytes.

**Whole exome sequencing (WES):** Sequencing by NGS the protein-coding region of the human genome (exome) that represents <2% of the genome, but contains most known disease-related variants.

---

**INTRODUCTION**

Primary ovarian insufficiency (POI), affects ~1% of women before 40 years’ age, being thus a relatively frequent syndrome [1]. POI is often diagnosed too late, causing irreversible impairment of fertility and well-being of the affected women. Recent data indicate that POI is associated with significant morbidity and mortality. Several of these risks are direct consequences of extra-ovarian defects generated by the gene mutations underlying some forms of POI [2]. The clinical relevance of POI has exponentially increased only very recently, particularly in economically advanced countries, due to the frequent choice of women to conceive after 30 years of age and the increased life expectancy.

POI can manifest as pubertal delay and primary amenorrhea (PA) or as secondary amenorrhea (SA) or oligomenorrhea of ≥4 months. Recurrence of menses and pregnancies can occur up to 22% of cases with SA up to 4 months [3], but spontaneous resumption of follicle activity is exceptional in cases with long-lasting SA. The POI-associated hypergonadotrophic hypogonadisms is defined as elevation of **follicle stimulating hormone (FSH)** (see glossary) ≥ 25 IU/L confirmed twice 30 days apart in women with SA [1]. The **ovarian reserve (OR)** can be evaluated by transvaginal ovarian ultrasound (US) with antral follicular count and/or by anti-**Müllerian hormone (AMH)** determination. Both in PA and SA cases, it is possible to uncover a certain ovarian reserve by US and AMH measurement [4].

Low/undetectable AMH indicates a dramatic diminution of the ovarian reserve predicting poor success of fertility preservation. However, follicular activity and pregnancy were rescued in POI patients with undetectable serum AMH after in vitro activation (IVA) and auto-transplantation of fresh tissue [5].
Menstrual irregularities, such as oligoamenorrhea or polymenorrhea, can anticipate the onset of SA, but not as a rule.

Many clinicians are unaware of the advantages of early POI diagnosis and fail to provide integrated personal care to address all the clinical needs. Here, we review the pathophysiology, genetics and treatment of POI in order to shed light on: a) the manifestations that should alert clinicians; and b) the novel multidisciplinary approaches for improved clinical management.

Iatrogenic POI frequently occurs in cancer survivors of young age. A variety of environmental factors such as infections or pollutants like phthalates, bisphenol A and polycyclic aromatic hydrocarbons from cigarette smoke, have a harmful impact on reproduction and are implicated in about 10% of POI [6]. Pollutants can affect ovarian follicles mainly by binding to estrogen or aryl hydrocarbon receptors, severely affecting follicle growth and viability [7]. Moreover, pollutants can cause germline epigenetic modifications, thereby accounting for transgenerational inheritance of reduced ovarian reserve [8]. About 5-30% of POI may have autoimmune origin [9], which is of potential interest because an early diagnosis may allow prompt treatment and eventually prevent damage to the ovarian reserve.

The incidence of familial cases of premature ovarian failure was reported to vary from 4 to 31% [10,11]. Thorough evaluation of alleged affected relatives showed a lower incidence than the original family history suggested of 12.7% [12]. Pedigree studies on affected families showed a mode of inheritance suggestive of autosomal dominant or recessive transmission with highly variable expressivity or X-linked inheritance with incomplete penetrance [13]. Approximately 2-6% of women with sporadic POI have a premutation of the FMR1 gene [14]. Other known genetic causes are responsible for a small proportion of POIs.

Most causes of POI are unknown. Understanding of the underlying molecular mechanisms is essential to develop strategies for prevention, early diagnosis and improved management of POI.

A great leap in the genetics of POI was achieved by the major methodological progress of Next Generation Sequencing (NGS) and in particular Whole Exome Sequencing (WES). The knowledge of more than 60 genes has enabled genetic diagnosis by NGS and provided a flow chart for the diagnosis and treatment of POI. A novel innovative treatment of the infertility of these patients has recently emerged.
Primordial follicles (PF) constitute the entire OR. Mechanisms that regulate the formation of the PF pool and the rate by which it is used will determine the duration of the fertile lifespan (Figures 1, 2). OR formation is a similar process in humans and mice, and in recent years, much insight has been gained into the molecular mechanisms involved.

At 20 weeks of gestation, a pair of human ovaries contains close to 7 million germ cells [15]. A rapid loss of follicles in fetal life results in about 1-2 million oocytes at birth. Prior to puberty the number has declined further to 300,000-400,000. During reproductive life, the number declines steadily until a critical threshold of 1000 primordial follicles is reached [15]. Below this threshold, ovulations cannot be supported, yielding menopause.

Oocytes derive from primordial germ cells (PGCs), which emerge from the extraembryonic mesoderm and migrate to the genital ridge (Figure 1). Upon arrival in the gonad, the PGCs will yield interconnected oogonia which, together with aggregation of germ cells, create so-called germ cell cysts [16]. Somatic cell-derived factors, in particular bone morphogenetic factors (BMPs) and Wnt3/β-catenin, control the commitment, migration and proliferation of PGCs. These signaling pathways induce the reacquisition of pluripotency, which is driven by Prdm1 and Prdm14. Subsequently, pluripotency genes (Pou5F1 encoding Oct4, Nanog, Klf4, Lin 28a) and germline specific genes (early genes: Nanos3, Kitlg, Tfapc2, Dppa3; late genes: Ddx4 or Vasa, Mael, Dazl) play important roles in the migration, proliferation and survival of PGCs [16]. After cessation of mitosis, the oogonia enter meiosis (13.5 dpc in mouse and asynchronously ~10-12 weeks of gestation in humans) and become oocytes (Figures 1 and 2). They will progress through the initial stages of prophase I until arrest in diplotene stage of prophase I. The initiation of meiosis is dependent on expression of Dazl, which induces responsiveness to retinoic acid, which in turn induces Stra8 (stimulated by retinoic acid)-dependent and -independent pathways, and subsequently the activation of the synaptonemal complex proteins Sycp1, 2, and 3. Recently, Taf4b was identified as an upstream regulator of several meiotic genes, including Stra8 and Dazl, in mice and women [17]. Additionally it recently appeared that post-transcriptional
mechanisms involving the Ythdc2/Meioc complex are mandatory for the proper mitotic/meiotic transition [18,19].

The next developmental step in follicle formation is the breakdown of germ cell cysts between E17.5 and 5 dpp in mice and at mid gestation (10-13 weeks of gestation) in humans (Figure 1). Upon breakdown pregranulosa cells are recruited to encapsulate a single oocyte to form PF, and oocytes undergo meiotic arrest. Gdf9, Bmp15, FoxL2, Nobox, Figla, Notch2, and Adam10 include some of the factors that affect the timing of cyst breakdown and differentiation of pregranulosa cells [20,21]. Furthermore, estrogen signaling plays an inhibitory role in cyst breakdown [22]. At the cessation of mitosis, the number of oogonia has increased exponentially. However, it is estimated that during cyst breakdown, two thirds of the oocytes are lost through programmed cell death, including apoptosis and autophagy [23].

Genetic modification in mice has been beneficial to identify the crucial genes in establishment of the ovarian reserve. Mutations in several of these genes have been identified in women bearing POI.

**RECENT ADVANCES IN THE GENETICS OF POI IN HUMANS**

The genetic causes of POI are highly heterogeneous with isolated or syndromic forms. Reproductive and extra-reproductive features of syndromic POI are described in Table 1. The genes involved are listed in Figures 1-3 and Table 1.

**MEIOSIS, DNA REPAIR AND POI**

Mutations of meiotic and DNA repair genes are responsible for syndromic and non-syndromic POI (Figures 2 and 3). There have been recent major advances in the identification of these genes as a cause of POI through NGS studies.
Oocytes enter into and progress through meiosis prophase I during fetal life. Mutations in meiotic genes usually impair meiotic progression and trigger oocyte death as evidenced by several mouse models [24].

During prophase I, meiosis requires the establishment of the synaptonemal complex (SC) and the generation and repair of DNA double strand breaks (DSB) [25]. Cohesin rings surrounding the chromosomes contribute to proper formation of the SC. Stromal antigen 3 (STAG3), Recombination 8 (REC8), Structural Maintenance of Chromosomes 1B (SMC1B) and Radiation Sensitive 21-Like (RAD21L) encode proteins belonging to the cohesin family and are specific to meiosis. Exome sequencing revealed that the two copies of STAG3 are inactivated by a truncating mutation in patients with POI from a consanguineous family [26]. Of note, one patient had bilateral ovarian tumors. Inactivation of Stag3 in mice impairs meiotic progression and leads to oocyte death [27]. SMC1B and REC8 have also been proposed to be associated with POI [28]. The SC is formed by several proteins organized in lateral and central elements [25]. A homozygous mutation of the Synaptonemal Complex Central Element Protein 1 (SYCE1) was described in two sisters with POI in a consanguineous family [29], being consistent with infertility observed in animal models [30].

Mini Chromosome Maintenance 8 and 9 are helicase members of the MCM family. MCM8-9 complex is required for homologous recombination (HR)-mediated repair of DSB, facilitating DNA resection by the MRN complex [31]. Lack of Mcm8 or Mcm9 in mice induces meiotic defects, oocyte degeneration and ovarian tumors. Regarding MCM8, the analysis of three consanguineous sisters with hypothyroidism and POI revealed the presence of a pathogenic variant [32]. The study of several other consanguineous families allowed the identification of homozygous variants for MCM8 and MCM9 in the affected patients[33–36]. For MCM8 and MCM9, the repair of chromosomal breaks in fibroblasts or lymphocytes of the patients was found altered [32,33].

Meiotic DSB repair requires the loading of two recombinases RAD51 and its meiotic paralog DMC1 on DNA. The activities of DMC1 and RAD51 are regulated by many factors including homologous-pairing protein 2 homolog (HOP2/PSMC3IP). Only one homozygous mutation in DMC1 has been reported in women with POI [37]. The study of a Palestinian family using homozygosity mapping and NGS allowed the detection of a homozygous microdeletion in the PSMC3IP gene [38]. The possibility of a meiotic defect in the patients studied was not examined
The recombination intermediates need to be stabilised to promote the formation of crossovers. This step requires helicases such as HFM1 and the dimer MSH4-MSH5. Exome sequencing has uncovered composite heterozygous mutations in HFM1 in a cohort of patients with sporadic POI and secondary amenorrhea [39,40], in agreement with the phenotype of the hfm1−/− mice. Exome sequencing recently identified a deleterious homozygous donor splice-site mutation in MSH4 in a case of familial POI. This mutation was associated with the generation of internally deleted MSH4 protein [41]. Similarly, a homozygous mutation in MSH5 in two sisters with POI has recently been reported [42]. The adverse effect of this mutation was confirmed in a mouse model and proven to impair DNA repair.

The final step of recombination is the resolution of recombination intermediates. The resolution of the double Holliday junctions (dHj) is believed to rely on the heterodimer MLH1-MLH3, and the exonuclease EXO1. Mice lacking either Mlh1 or Mlh3 are sterile. Human mutations reported in MLH1 are largely associated with colorectal cancer and Lynch syndrome with no systematic impact on fertility.

Three RecQ helicases, namely BLM (Bloom syndrome), RECQL4 (RecQ protein-like 4) and WRN (Werner syndrome) are proposed to be involved in meiotic recombination albeit their function in mammals is not fully elucidated. These RecQ helicases are also mutated in human syndromes manifesting in premature aging, cancer and often POI or reduced fertility [43–45].

Cockayne Syndrome B (CSB/ERCC6) encodes a protein involved in DNA repair. A heterozygous mutation in the CSB-piggyBac transposable element derived 3 (PGBD3) fusion gene-induced POI with the mutated protein exhibiting an altered response to DNA damage [46].

Lastly, though meiotic DSB repair appears to rely on homologous recombination, a second process for DSB repair, the non-homologous end-joining (NHEJ), allows the direct ligation of broken DNA ends to each other. X-ray repair cross-complementing protein 4 (XRCC4) and Ligase 4 (LIG4) are two proteins absolutely required for NHEJ. Syndromic POI was reported in a female patient with homozygous single nucleotide variant in the XRCC4 gene [47]. POI was reported in two patients with biallelic truncating mutations in the LIG4 gene [48]. These patients display short stature, microcephaly and genomic instability or hypersensitivity to radiation. Similarly, another important DNA repair pathway, the Fanconi anemia (FANC) pathway, exists
in numerous progenitor cells, including the germline. This pathway employs at least 20 proteins including those encoded by the FANCA, FANC and FANCG genes, and were associated with POI [49]. Mouse models for several Fanc genes (a, c, d, e, f, g, i, m, n, o, p) evidenced gonadal hypoplasia with ovaries showing follicle depletion [50]. This appears to be due to reduced primordial germ cell numbers though meiotic roles are also possible. Very recently a homozygous FANCM mutation was shown to underlie a familial case of non-syndromic POI [51]. FANCM biallelic mutations predispose to cancer, in particular early-onset breast cancer in females, and chemosensitivity [52–54]. These findings clearly support a genetic link between infertility and DNA-repair/cancer genes.

The recent identification of a genetic link between POI and tumor/cancer susceptibility genes (STAG3, MCM9, FANCM) makes the genetic diagnosis of all isolated cases of unexplained POI necessary, to perform an enhanced genetic counseling and long-term follow-up. Indeed POI patients can harbor mutations in such ‘cancer susceptibility’ genes. The large number of genes potentially involved will make these families among the most important involved in POI.

**GENES INVOLVED IN SYNDROMIC POI** (Figures 2, 3 and Table 1)

The clinical presentations of syndromic POI are highly variable and are presented in Table 1.

**Perrault syndrome** (PS)

Perrault syndrome (PS) is a genetically heterogeneous autosomal recessive syndrome mainly characterized by ovarian dysfunction and sensorineural deafness (see Table 1). Recently, a growing number of genes involved in PS was identified by NGS. These genes are implicated in mitochondrial functions or metabolism. In mouse models genetic changes that cause perturbation in mitochondrial protein translation lead to hearing loss as a result of tissue-specific apoptosis [55]. Given the role of apoptosis in ovarian development, inappropriately timed apoptosis may also lead to POI. HARS2 [56] and LARS2 [57,58] encode mitochondrial histidyl or leucyl-tRNA synthetases involved in translation of mitochondrially encoded genes. CLPP encodes a highly conserved endopeptidase component of a mitochondrial ATP-dependent proteolytic complex, involved in degradation of unfolded or misfolded polypeptides [59–61]. C10orf2 encodes
Twinkle, a mitochondrial primase-helicase essential for mitochondrial DNA replication [62,63], yielding a mitochondrial DNA depletion syndrome and progressive external ophthalmoplegia. Very recently mutations of *ERAL1* and *KIAA0391* were involved in PS. *ERAL1* protein binds to the mitochondrial 12S rRNA and is involved in assembly of the small mitochondrial ribosomal subunit affecting mitochondrial respiration and function [64]. *KIAA091* encodes RNase P (PRORP) the metallonuclease subunit of the mitochondrial RNase P complex responsible for the 5'-end processing of mitochondrial precursor tRNAs [65].

Apart from mitochondrial functions, mutations in a multifunctional peroxisomal enzyme involved in fatty acid β-oxidation and steroid metabolism, 17β-hydroxysteroid dehydrogenase type 4 (*HSD17B4*, also known as D-bifunctional protein (*DBP*)) also cause PS [66–68]. Mutations of this gene were already identified in autosomal recessive mode in a severe disorder of peroxisomal fatty acid β-oxidation. A combination of two homozygous mutations leading to a coincidental PS, one in *CLDN14* involved in deafness and the other in *shugoshin-like 2a* (*SGO2*) encoding shugoshin2, likely involved in POI, have been described [69]. In the mouse *SGO2* maintains during meiosis the integrity of the cohesion complex that tethers sister chromatids. Unsolved cases of PS persist, indicating that novel genes will still be discovered [70,71].

### Premature aging syndromes

Laminopathy due to mutations in *LMNA* encoding a nuclear envelope protein includes ovarian failure and premature aging. The Malouf syndrome belongs to this condition [72]. The Hutchinson-Gilford Progeria Syndrome (HGPS) [73], caused by aberrant splicing of the *LMNA* gene and expression of a mutant product called progerin, comprises premature aging and lipodystrophies. Sometimes both syndromes occur together [73].

GAPO syndrome, another form of premature aging and premature follicle depletion, is caused by mutations of the anthrax toxin receptor 1 gene *ANTXR1* [74]. The protein has been involved in cell attachment and migration. Additionally, it allows the interaction of cells and several components of the extracellular matrix by binding extracellular ligands with the actin of cytoskeleton.

### Neurosensory syndromes
Leukoencephalopathies are also a heterogeneous group of disorders associated with vanishing white matter (VWM) and in a subset POI yielding ovarioleukodystrophy. Mutations of a specific mitochondrial alanine aminoacyl-tRNA synthetase, AARS2, have been involved [75,76]. Another group of genes involved is *EIF2B1* to *EIF2B5* which encode the five subunits of the eukaryotic initiation factor 2B [77].

Mutations in *RCBTB1* [78] are present in a syndrome including inherited retinal dystrophy and POI. *RCBTB1* is involved in ubiquitination, more specifically as a CUL3 substrate adaptor involved in stress-response to combat oxidative or electrophilic insults.

Mutations of the nuclear gene *POLG* encoding a mitochondrial DNA polymerase gamma can lead to POI with autosomal dominant progressive external ophthalmoplegia [79].

Defects in the respiratory chain or mitochondrial ATP synthase (complex V) result in mitochondrial dysfunction and defective energy production. Mutations of *MT-ATP6/8* encoding two of the subunits of complex V are associated with a syndrome including cerebellar ataxia, peripheral neuropathy, diabetes mellitus and POI [80].

**Skeletal syndromes**

POI can occur in some skeletal syndromes such as Demirhan syndrome caused by mutations in *BMPR1B* [81].

Another condition including proximal synphalangism and POI is caused by mutations in *NOG* [82]. NOG protein is expressed in the ovaries and interacts with BMP which plays an important role in ovarian function.

**GENES ASSOCIATED WITH NON-SYNDROMIC POI** (Figures 2, 3)

**REGULATION OF PRIMORDIAL FOLLICLE RECRUITMENT**

The majority of PF will remain dormant until stimulatory signals or a break from inhibitory signals induces activation. PF recruitment is initiated in mice after birth at PND 4-5, and in humans at 17 weeks of gestation (Figure 1).

Various oocyte-expressed signaling and/or transcription factors have been identified to maintain the quiescent state (Foxo3, Lhx8) or, in contrast, to activate PF growth (Sohlh1, Sohlh2, Nobox)
Interestingly, Foxo3 and Lhx8 are the effectors of the PI3K/Akt signaling pathway [84]. Targeted (oocyte-specific) deletion of stimulating factors (Kit, Pdpk1, Rptor, Rps6) of this pathway blocks follicular activation and induces PF apoptosis, whereas loss of the inhibiting factors (Pten, Cdkn1b, Tsc1, Tsc2, Stk11) results in premature and global activation of PF [85] (Figure 2).

A characteristic of PF activation is the transition of squamous pre-granulosa cells to cuboidal granulosa cells. Failure thereof results in an arrest at the primordial stage followed by oocyte death and follicular depletion, as shown in FoxL2 knockout mice [86]. AMH, expressed during this transition, inhibits PF activation since Amh knockout mice display an accelerated exhaustion of the pool [87]. Several additional growth factors have been shown to activate primordial follicle recruitment (Figure 2).

**REGULATION OF FOLLICLE GROWTH**

**Gonadotropin-independent phase: role of ovarian growth factors**

Early follicle growth up to the large preantral stage is independent of gonadotropins in rodents and relies on intraovarian factors (Figure 2). It requires a coordinated dialog between the oocyte and granulosa cells in which gap junctions, and SMAD and PI3K/Akt pathways are important. The discovery that follicles in ovaries of Gdf9 knockout mice fail to develop beyond the primary stage was the first of a series showing the importance of factors involving SMAD signaling pathway in follicle development [88]. Furthermore, in the oocyte-knockout of Furin, a pro-hormone convertase responsible for proteolytic cleavage of TGFβ family members, follicle growth is arrested at the secondary stage [89]. Likewise, inhibition of the PI3K/Akt pathway by Kit or Kitlg deletions leads to the blockage of follicular growth at the primary follicle stage. Using targeted deletion or activation of Igf1, Igf1r, Irs2, Rictor or Foxo3, it was shown that the PI3K-Akt signaling pathway not only plays a role in primordial follicle activation, but also in follicle survival and development beyond the primary stage [90,91] (Figure 2).

**Gonadotropin-dependent phase: role of gonadotropins**

The progression through final stages of follicle development depends on the gonadotropins FSH and LH (Figure 2). The threshold for FSH sensitivity is determined by interplay between various
stimulatory and inhibitory growth factors, such as IGF1 and various TGFβ family members tipping the balance to either follicle survival or atresia. Deletion of the Fshr yields an enhanced rate of atresia and follicles fail to progress to the antral stage [92]. Targeted deletion of the non-canonical progesterone receptor Pgrmc1 in granulosa cells suppressed antral follicle development and increased atresia [93]. Finally, LH action is indispensable for ovulation, meiotic resumption of the oocytes, and cumulus expansion. Loss of LH action therefore also results in infertility as follicle development is blocked at the antral stage [94]. In the absence of sex steroid action, the final stages of follicle development show abnormalities leading to follicular arrest as illustrated in mouse models lacking (cell-specific) androgen or estrogen function [95,96].

**Defects in human genes in non syndromic POI**

Interestingly there is an overlap between genes involved in the onset of puberty, normal reproductive aging and POI [97]. We will present only recent data or selected examples of genes that illustrate the precaution that must be taken in the interpretation of genetic data and comparison with animal models.

**Genes involved in establishment of the primordial follicle pool and maturation to primary follicles**

Heterozygous variants of SOHLH1 and SOHLH2 have been found in POI [98]. Interestingly two families harbouring a homozygous single-base deletion in the coding region or a premature stop codon of SOHLH1 [99] had primary amenorrhea, lack of secondary sex characteristics and non-visualized ovaries.

A recessive missense mutation in Nucleoporin-107 was identified in a consanguineous family of Palestinian origin [100]. NUP107 is a component of the nuclear pore complex, and the NUP107-associated protein SEH1 is required for oogenesis in *Drosophila*. In *Drosophila*, Nup107
knockdown in somatic gonadal cells resulted in female sterility, whereas males were fully fertile. 
*Nup107* mutations may compromise the meiotic DNA damage response, leading to oocyte death.

A heterozygous stop codon was identified in the eukaryotic translation initiation factor 4E nuclear import factor 1 gene *elf4ENIF1* in familial POI with dominant inheritance in three generations [101]. The gene plays an important role in oocyte development in organisms from *Drosophila* to mice.

Heterozygous mutations of the *Newborn ovary homeobox* (*NOBOX*) transcription factor have been reported in women with sporadic POI [28,102,103]. Contrasting with the knock-out mouse model which displays accelerated postnatal oocyte loss due to a defect in germ cell cyst breakdown [104], patients with *NOBOX* mutations may have primary or secondary amenorrhea with follicles detected in adulthood in the ovaries by histology [102]. This may be due to the fact that the human mutations caused only partial loss of function *in vitro*. Functional studies are thus critical before any comparison with animal models and before any conclusion on the human physiological role of a gene can be established. Interestingly, a prevalence of 5.6 and 6.2% of heterozygous mutations has been detected in different cohorts making this gene potentially one of the most frequent causes of POI in humans, provided that causality of the heterozygous variants is proven. Recently, a homozygous truncated variant of *NOBOX* has been described [105], with complete loss of function *in vitro* in patients with primary amenorrhea, but with no ovarian phenotype. Fertility of the heterozygous mother excludes a mechanism of haploinsufficiency as previously proposed.

**Genes involved in the maturation and growth from primary to ovulatory follicles**

The two steroid hormone receptors, for estrogens (*ESR1*) and androgens (*AR*), are positive regulators of follicular maturation. Two families with homozygous mutations of *ESR1* have been described. The probands had primary amenorrhea without breast development, very high estrogen plasma concentrations and multicystic ovaries [106,107]. Functional studies reveal altered estrogen signaling.

Interestingly, a continuum of phenotypes is associated with *FSHR* mutations varying from
absence of pubertal maturation to normal breast development with secondary amenorrhea, according to severity of the receptor inactivation [108–111]. The first mutation described in the Finnish population was associated with the existence of preantral or rare antral follicles in the ovaries [108]. However functional studies have shown that it was a partial loss of function mutation [112]. A complete loss of function mutation of the FSHR has also been described, causing primary amenorrhea and complete block of follicular maturation after the primary stage [113]. Remarkably there was an increased density of small follicles when compared to an age-matched woman. Thus, the gonadotropin-dependent growth phase in humans starts at the primary follicle stage contrary to rodents in which preantral follicles are observed in ovaries of mice deficient of Fshb or Fshr (see above). Thus caution must be taken before extrapolating data from mouse models to humans. Partial mutations of the FSHR are associated with secondary amenorrhea and the presence of different-sized antral follicles depending on severity of the mutation [114]. Of note, there is a correlation between the phenotype of the patients and the molecular studies. Because of the existence of follicles in the ovaries in vitro maturation may be obtained and fertility restored [115] and see below.

Mutations in the other gonadotropin receptor gene, LHCGR, cause POI with secondary amenorrhea, anovulation and recurrent cysts formation. In the affected families disorders of sex differentiation are found in male relatives with hypogonadism due to Leydig cell hypoplasia [116,117].

The first involvement of BMP15 in POI was reported in an Italian family with 46,XX ovarian dysgenesis [118]. Since then, several heterozygous and one homozygous BMP15 variants were associated with primary or secondary amenorrhea, but streak ovaries were found without follicles by ultrasound, which was interpreted as premature depletion of the ovarian reserve [118]. Functional studies support impaired production of the mature protein or a dominant negative effect in some cases [118]. However, most of the variants detected occur in heterozygous state, and BMP15 haploinsufficiency was proposed to have a predisposing impact for POI. It was also proposed that reduced BMP15 dosage would contribute to the ovarian phenotype of Turner syndrome patients [119]. These conclusions were challenged by a very recent work on a family with a BMP15 knockout-like effect [120], with both parents bearing deletions in the proregion of the BMP15 precursor. The heterozygous mother conceived normally and had three children. Thus, it seems that haploinsufficiency is not involved in
humans. Most of the mutations of BMP15 described were heterozygous and a mechanism of haploinsufficiency or a dominant negative effect was suspected but most often not demonstrated, making it impossible to implicate the corresponding gene as the unique cause of POI. Additional genetic mutations in an oligogenic mode of inheritance and/or environmental factors must be involved. Despite streak ovaries, AMH was initially detectable in the two POI sisters bearing both deletions of BMP15, supporting the presence of an ovarian reserve [120]. Five years later, however, AMH was not detected in both sisters, probably because of exhaustion of the primordial follicle pool, and one sister had received an egg donation.

In case POI is due to a block in follicular maturation urgent fertility preservation is thus needed to avoid follicular atresia.

A recent study showed a homozygous single base deletion in the coding region of GDF9 in POI with PA [121] confirming the causative role of this gene.

**INNOVATIVE TREATMENTS FOR POI**

The most frequent therapeutic approach of infertility of POI patients is embryo transfer from donated oocytes. Given the complexity of this therapeutic approach, couples requiring oocyte donation should discuss its medical, ethical, legal and psychological aspects with medical experts. Recently, a new innovative fertility treatment has been developed for POI (Figure 4).

Premature activation of primordial follicles caused by chemotherapy, particularly cyclophosphamide, is a significant cause of the disappearance of follicles from the ovaries. Fertility preservation through tissue cryopreservation before chemotherapy is therefore an important method to prevent POI [122]. Post treatment, the tissue can be auto-transplanted. Infants have been born as a result of the technique.

For cancer patients at high risk of re-introduction of the malignancy, such as leukemia, *in vitro* maturation of follicles all the way to metaphase II oocytes is a much needed therapy that still remains to be developed.
In early stages of ovarian insufficiency there are primordial follicles left in the ovaries. Hence, cryopreservation of ovarian tissue as fertility preservation should be carried out as soon as the risk of follicular decrease has been identified. Although, these primordial follicles are inactive, Hovatta et al. [123] showed that human ovarian follicles can be activated when ovarian tissue is cut into small pieces and placed in organ culture. Recently, Hippo signaling was identified as the regulatory factor in this activation [5,124]. When residual follicles in ovarian tissue from POI patients were stimulated by cutting the tissue into small pieces, and subsequently exposed to phosphatase and tensin homolog (PTEN) inhibitors and protein kinase B (Akt) activators prior to transplantation, full oocyte maturation can be achieved [125] (Figure 4). Of note, PTEN is also an important tumor-suppressor, and therefore its inactivation in vivo might be risky. After in vitro activation (IVA), the follicles have to be stimulated to grow, and FSH stimulation is used in a similar manner as in ovulation induction or before in vitro fertilization treatments. Transplantation of the ovarian tissue back to patients after IVA has been performed and healthy infants have been born (Figure 4). This IVA method is useful for those patients who may have residual follicles left in their ovaries (See flow chart for POI diagnosis and treatment Figure 5).

Ultimately recent technological developments with induced pluripotent stem cells (iPS) allow the reconstitution of complete oogenesis [126]. Although this has currently only been achieved in the mouse, advances with human cells make it now conceivable for modeling POI and would prove invaluable for supporting genetic diagnosis. In specific cases (e.g. altered follicle recruitment or growth), such models may prove useful for drug screening and selecting the most appropriate treatment.

Other technological developments such as the tissue engineering to generate ovarian implants able to restore fertility are promising leads that may help restoring fertility [127].

**CONCLUDING REMARKS AND FUTURE PERSPECTIVES:**

Taken together, the vast technological advancements have provided valuable new information on the molecular pathophysiology of POI and its new diagnosis and treatment opportunities. Information derived from recent genetic studies has improved the accuracy of POI diagnosis and
may reveal new targets for the treatment of infertility or for contraception in the future. Because of its increased non-reproductive morbidity and mortality (e.g. autoimmunity and tumors) POI should be followed by a multidisciplinary team. The very recent identification of a link between POI and tumor susceptibility makes the genetic diagnosis of all isolated cases of unexplained POI necessary. Also, POI as a genetic disorder becomes amenable to innovative therapies unlike most other genetic diseases. This obviously necessitates the presence of remnant ovarian reserve that has to be evaluated besides conventional methods by genetic studies (Figure 5). Indeed the key question is: what is the state of the follicular pool in the POI patient? The mutated gene may provide important information on the ovarian reserve depending on its level of action during either establishment and/or maintenance of the follicular pool, or follicular growth. This belongs to the questions that will need to be answered in the future (see outstanding questions box).

**FIGURE LEGENDS**

**Figure 1: Formation of the ovarian reserve in humans and mice.**

Top: Chronology of female germ cells development from primordial germ cell (PGC) specification until follicle formation (purple). Appearance of oogonia and meiotic cells are defined respectively by the blue and red lines [weeks post fertilization (wpf), days post conception (dpc), days post-partum (dpp)]. Middle: Schematic presentation of the various germ cell stages. From left to right, migratory PGCs, oogonia, pre-leptotene, leptotene, zygotene, pachytene and diplotene arrested oocytes in primordial and growing (primary) follicles are presented in blue. Key signaling pathways regulating PGC specification, meiotic entry and follicle activation are provided in green. BMPs, bone morphogenic proteins; PRDM, PR domain containing 1, with ZNF domain (PRDM1/BLIMP1); RA, retinoic acid; STRA8, stimulated by retinoic acid 8; CYP26B1, cytochrome P450, family 26, subfamily B, polypeptide 1; KITL, kit ligand; FOXO3, forkhead box O3; PI3K, phosphoinositide-3-kinase; PTEN, phosphatase and tensin homolog. Bottom: Frequently used markers of the various germ cell stages. POU5F1 (OCT4), POU class 5 homeobox 1 and TFAP2C (AP2 γ) are retrieved in PGC and oogonia with stem cell potential. DAZL, deleted in azoospermia-like and DDX4 (VASA), DEAD box
polypeptide 4, mark the gametogenic competency acquired when mouse germ cells colonize the
gonad and later during oogonial differentiation in the human ovary. STRA8 is expressed at the
mitotic/meiotic switch, in pre-leptotene stage and SYCP3 is a synaptonemal complex protein that
labels the axes of the chromosomes during meiotic prophase I. NOBOX, NOBOX oogenesis
homeobox, and TP63, tumor protein 63, are retrieved in the nuclei of diplotene-arrested oocytes
enclosed into follicles.

Figure 2: Human genes associated with POI and their physiological importance in
oogenesis, folliculogenesis and other functions.

Genes with in vivo mutations associated with POI in human and their physiological importance
in ovarian function are indicated. Oogenesis and folliculogenic processes are represented by a
transit between different compartmental stages depicted as boxes containing the cell populations.
At each stage of oogenesis and folliculogenesis, an important part of the germ cells will die by
apoptosis, depicted by a concomitant decrease in boxes sizes. The first compartment (yellow
box) corresponds to the primordial germ cells (PGC) when they differentiate into oogonia, the
second compartment (green box) corresponds to follicle formation, which involves meiosis and
follicular assembly processes and ends with establishment of the ovarian reserve of primordial
follicles (pink box). From this reserve, follicular activation leads to the formation of primary
follicles (light blue box). Then the growing follicles can reach the antral stage (dark blue box)
and ovulate, or degenerate by atresia. Genes whose mutations are associated with POI are
indicated at each stage of these developmental processes. The involvement of each gene at a
specific stage of ovarian or follicular development is based on in vivo (presence/absence of
follicles in biopsy samples, detection of antral follicles using ovarian ultrasound scanning or
AMH measurements in women carrying mutations) or/and in vitro observations (culture
experiments using human ovarian cortex or granulosa cells). For genes depicted in italic,
information on their stage specific role is only available from mouse models. Genes associated
with POI for which the stage-specific role is unknown are listed in the box, with their biological
function (green font). The stimulating and inhibiting factors are depicted in black and red font,
respectively. See text for references and [13].
**Figure 3: Female infertility, meiotic recombination and DNA repair**

The various steps of meiotic recombination and specific genes involved (non-exhaustive, middle panel) are presented in the middle panel. Genes suspected in POI cases are in bold. Left panel shows the structure of the synaptonemal complex required for completing recombination. Right panel presents representative germ cells at oogonial (A), leptotene (B), zygotene (C), pachytene (D) and diplotene (primordial follicle, E) stages respectively from human ovaries at 8, 12, 15, 21 and 27 weeks post-fertilization.

**Figure 4: In vitro activation of dormant follicles**

Ovarian cortical tissue is laparoscopically biopsied from the woman undergoing POI. The tissue is cut to slices for activating Hippo signaling and initiation of follicular growth. Sliced tissue is then activated using a PTEN inhibitor or AKT stimulator *in vitro* for 24 hours. Thereafter the tissue pieces can be transplanted back to the ovary of the donor woman. The activated follicles are stimulated using human recombinant FSH for 6-10 days, until 15-17 mm size antral follicles are seen by ultrasonography. The woman will be given human recombinant LH to induce the final maturation of the oocytes. The oocytes are collected 36 hours later using transvaginal ultrasound-guided needle aspiration. They are injected by intracytoplasmic sperm injection (ICSI) with sperms from the partner. The embryos are cultured for 3 to 5 days, and the morphologically best embryo will be transferred to the intravaginal progesterone-treated female partner’s womb, and the rest of the embryos are cryo-stored for future transfers.

**Figure 5: Flow chart for POI diagnosis and treatment**

After the initial diagnosis of POI, family investigation and evaluation of the follicular reserve by AMH assay and antral follicular count (AFC) are performed. Specific causes are eliminated. In case of unexplained POI karyotype and FMR1 study are performed. In all cases hormonal treatment has to be started. In isolated POI array CGH (aCGH) or NGS can highlight defects in genes involved in ovarian differentiation or in the establishment of the follicular pool. This together with the undetectable ovarian reserve will lead to genetic counseling in the patient and
relatives and therapeutic counseling for the patient’s infertility by a multidisciplinary team. If there is a wish to conceive egg donation will be performed. In case there is a detectable ovarian reserve and/or a defect in genes involved in follicular maturation genetic counselling will be performed in the patient and relatives and therapeutic counseling will lead to fertility preservation. In the future in vitro activation of small follicles (IVA) might be performed. In syndromic POI NGS of specific genes will be performed according to the clinical phenotype of the patient. Specific treatment of associated symptoms is needed.
<table>
<thead>
<tr>
<th>Diagnosis</th>
<th>Menstrual history</th>
<th>Ovarian phenotype</th>
<th>Particular features</th>
<th>OMIM</th>
<th>Gene(s) involved</th>
</tr>
</thead>
<tbody>
<tr>
<td>WT1-related XX-DSD</td>
<td>PA or SA</td>
<td>Streak gonads partial ovarian dysgenesis</td>
<td>Nephropathy, diaphragmatic hernia</td>
<td>#194070</td>
<td>WT1</td>
</tr>
<tr>
<td>SF1-related XX-DSD</td>
<td>PA or SA</td>
<td>Streak gonads partial ovarian dysgenesis</td>
<td>Adrenal insufficiency</td>
<td>#612964</td>
<td>NR5A1/SF1</td>
</tr>
<tr>
<td>BPES</td>
<td>PA or SA</td>
<td>Rare or absent follicles</td>
<td>Blepharophimosis, ptosis, epicanthus inversus</td>
<td>#110100</td>
<td></td>
</tr>
<tr>
<td>FMR1 premutation</td>
<td>SA</td>
<td>Follicle depletion</td>
<td>X linked mental retardation in family. Fragile X tremor/ataxia syndrome</td>
<td>#300624</td>
<td>FMR1</td>
</tr>
<tr>
<td>Autoimmune Polyendocrinopathy Syndrome. APS-PGA type 1</td>
<td>PA or SA</td>
<td>Autoimmune oophoritis</td>
<td>Addison disease, candidiasis, vitiligo, hypoparathyroidism, diabetes mellitus, hepatitis, malabsorption, keratopathy, alopecia</td>
<td>#240300</td>
<td>AIRE</td>
</tr>
<tr>
<td>Autoimmune APS-PGA type 3</td>
<td></td>
<td>Autoimmune oophoritis</td>
<td>Autoimmune thyroid disease, atrophic gastritis, vitiligo</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pseudohypoparathyroidism</td>
<td>SA</td>
<td>Follicular cysts but no corpora lutea in one case</td>
<td>Brachydactyly, short stature, hypocalcemia and hyperphosphatemia, hypothyroidism, obesity</td>
<td>#103580</td>
<td>GNAS</td>
</tr>
<tr>
<td>Galactosemia</td>
<td>PA</td>
<td>Streak ovaries or few non maturated follicles</td>
<td>Neonatal jaundice, failure to thrive, cirrhosis, cataract, intellectual disability, food intolerance, hypoglycemia, renal dysfunction.</td>
<td>#230400</td>
<td>GALT</td>
</tr>
<tr>
<td>Disorders of glycosylation (CDG1A)</td>
<td>PA</td>
<td>Absent ovaries in some patients by US or laparoscopy</td>
<td>Growth retardation, microcephaly, encephalopathy, peripheral neuropathy, retinitis pigmentosa, cardiac myopathy, hepatomegaly, nephrotic syndrome, psychomotor retardation</td>
<td>#212065</td>
<td>PMM2</td>
</tr>
<tr>
<td>Ataxia telangiectasia</td>
<td>PA</td>
<td></td>
<td>Cerebellar ataxia, telangiectasia, recurrent infections, malignancies and increased levels of alpha fetoprotein.</td>
<td>#208900</td>
<td>ATM</td>
</tr>
<tr>
<td>Nijmegen breakage syndrome</td>
<td>PA or SA</td>
<td>Streak gonads, small ovaries</td>
<td>Prenatal growth retardation, progressive mental deterioration, microcephaly, recurrent infections, increased risk for neoplasias</td>
<td>#251260</td>
<td>NBN</td>
</tr>
<tr>
<td>Condition</td>
<td>Type</td>
<td>Description</td>
<td>Symptoms</td>
<td>Genes</td>
<td></td>
</tr>
<tr>
<td>-----------------------------------</td>
<td>------</td>
<td>--------------------------------------------------</td>
<td>--------------------------------------------------------------------------</td>
<td>-------</td>
<td></td>
</tr>
<tr>
<td>Fanconi anemia</td>
<td>PA or SA</td>
<td>Decreased number of primordial follicles</td>
<td>Pancytopenia, small stature, microcephaly, ear anomalies, heart defects, kidney malformations, radial aplasia and thumb deformities, intellectual disability, café-au lait-spots</td>
<td>#227650, #227645, #614082</td>
<td>FANCA, FANCC, FANCG</td>
</tr>
<tr>
<td>XRCC4-related disorder</td>
<td>SA</td>
<td>Possibly accelerated follicular atresia</td>
<td>Short stature, microcephaly, developmental delay, diabetes mellitus</td>
<td>#616541</td>
<td>XRCC4</td>
</tr>
<tr>
<td>Bloom syndrome</td>
<td>SA</td>
<td>Possibly accelerated follicular atresia</td>
<td>Premature aging with chromosomal instability, short stature, skin rashes and telangiectatic skin on sun-exposed areas, increased risk for neoplasias, immunodeficiency</td>
<td>#210900</td>
<td>BLM</td>
</tr>
<tr>
<td>Werner syndrome</td>
<td>SA</td>
<td>Possibly accelerated follicular atresia</td>
<td>Premature aging with chromosomal instability, growth deficiency, sclerodermic skin changes, cataract, arteriosclerosis, increased cancer risk, diabetes mellitus</td>
<td>#277700</td>
<td>WRN</td>
</tr>
<tr>
<td>Rothmund-Thomson syndrome</td>
<td>SA</td>
<td>Gonadotropin resistance</td>
<td>Short stature, cataract, saddle nose, teeth anomalies, premature graying of hair</td>
<td>#268400</td>
<td>RECQL4</td>
</tr>
<tr>
<td>Hutchinson-Gilford progeria</td>
<td>SA</td>
<td>Diminished follicular reserve</td>
<td>Progeria, short stature, low body weight, early loss of hair, lipodystrophy, scleroderma, decreased joint mobility, osteolysis, cardiomyopathy</td>
<td>#176670</td>
<td>LMNA</td>
</tr>
<tr>
<td>GAPO</td>
<td>SA</td>
<td>Follicle depletion</td>
<td>Growth retardation, alopecia, pseudoanodontia, optic atrophy, high forehead, midface hypoplasia</td>
<td>#230740</td>
<td>ANTXR1</td>
</tr>
<tr>
<td>Perrault syndrome</td>
<td>PA, SA</td>
<td>Streak ovaries, lack of ovaries, small ovaries</td>
<td>Deafness, Neurologic symptoms in PRLTS1, PRLTS3 and PRLTS5</td>
<td>#233400, #614926, #614129, #615300, #616138</td>
<td>HSD17B4, HARS2, LARS2, CLPP, C10orf2, CLDN14+, SGO2</td>
</tr>
<tr>
<td>Condition</td>
<td>Affected</td>
<td>Clinical Features</td>
<td>Genes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>-----------</td>
<td>----------</td>
<td>-------------------</td>
<td>-------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Woodhouse-Sakati syndrome</td>
<td>PA</td>
<td>Streak ovaries</td>
<td>Alopecia, deafness, hypogonadism, diabetes, hypogonadism, intellectual disability</td>
<td>KIAA0391, ERAL1</td>
<td></td>
</tr>
<tr>
<td>Vanishing white matter disease Ovarioleukodystrophy</td>
<td>SA</td>
<td>Ovarioleukodystrophy streak ovaries</td>
<td>Progressive cerebellar ataxia, spasticity, cognitive impairment with white matter lesions on brain imaging. Onset from early infancy to adulthood</td>
<td>#241080, C2orf37</td>
<td></td>
</tr>
<tr>
<td>Retinal dystrophy with or without extraocular anomalies</td>
<td>SA</td>
<td></td>
<td>Retinal dystrophy, goiter, intellectual disability, hypogonadism</td>
<td>#603896, EIF2B, AARS2</td>
<td></td>
</tr>
<tr>
<td>Progressive external ophthalmoplegia</td>
<td>SA</td>
<td>Diminished follicle reserve</td>
<td>Ptosis, progressive external ophthalmoplegia, sensorineural hearing loss, axonal neuropathy, muscle weakness, ataxia, dysarthria, dysphagia and late onset Parkinsonism</td>
<td>#157640, POLG</td>
<td></td>
</tr>
<tr>
<td>Acromesomelic chondrodysplasia with genital anomalies</td>
<td>PA</td>
<td></td>
<td>Severe brachydactyly with radial deviation of the fingers, ulnar deviation of the hands, fusion of the carpal/tarsal bones, aplasia of the fibula, bilateral clubfeet with small broad feet and short toes</td>
<td>#609441, BMPR1B</td>
<td></td>
</tr>
<tr>
<td>Interphalangeal joint synostosis</td>
<td>SA</td>
<td></td>
<td>Symphalangism, hearing loss</td>
<td>#185800, NOG</td>
<td></td>
</tr>
</tbody>
</table>

PA, primary amenorrhea; SA, secondary amenorrhea, DSD: disorder of sexual differentiation. See text for references and [13].
AKNOWLEDGEMENTS

Apologies to those whose related publications were not cited due to space limitations. We thank Alain Gougeon for providing photographs of the different steps of follicular maturation.

REFERENCES


4. La Marca, A. et al. (2013) Prediction of age at menopause from assessment of ovarian reserve may be improved by using body mass index and smoking status. *PloS One* 8, e57005


Chen, Y. *et al.* (2007) Estradiol, progesterone, and genistein inhibit oocyte nest breakdown and 
primordial follicle assembly in the neonatal mouse ovary in vitro and in vivo. *Endocrinology* 148, 
3580–3590

Pepling, M.E. and Spradling, A.C. (2001) Mouse ovarian germ cell cysts undergo programmed 
breakdown to form primordial follicles. *Dev. Biol.* 234, 339–351

Biol.* 4 Suppl, s41-49

Genet.* 14, 794–806

949

Winters, T. *et al.* (2014) Meiotic cohesin STAG3 is required for chromosome axis formation and 
sister chromatid cohesion. *EMBO J.* 33, 1256–1270

Bouilly, J. *et al.* (2016) Identification of Multiple Gene Mutations Accounts for a New Genetic 

de Vries, L. *et al.* (2014) Exome sequencing reveals SYCE1 mutation associated with autosomal 

Bolcun-Filas, E. *et al.* (2009) Mutation of the mouse Syce1 gene disrupts synapsis and suggests a 
link between synaptonemal complex structural components and DNA repair. *PLoS Genet.* 5, 
e1000393

MRE11-RAD50-NBS1 complex. *Nat. Commun.* 6, 7744

AlAsiri, S. *et al.* (2015) Exome sequencing reveals MCM8 mutation underlies ovarian failure and 

Wood-Trageser, M.A. *et al.* (2014) MCM9 mutations are associated with ovarian failure, short 
stature, and chromosomal instability. *Am. J. Hum. Genet.* 95, 754–762

Tenenbaum-Rakover, Y. *et al.* (2015) Minichromosome maintenance complex component 8 

Fauchereau, F. *et al.* (2016) A non-sense MCM9 mutation in a familial case of primary ovarian 

Goldberg, Y. *et al.* (2015) Mutated MCM9 is associated with predisposition to hereditary mixed 
polyposis and colorectal cancer in addition to primary ovarian failure. *Cancer Genet.* 208, 621–624

Mandon-Pépin, B. *et al.* (2008) Genetic investigation of four meiotic genes in women with 

Zangen, D. *et al.* (2011) XX ovarian dysgenesis is caused by a PSMC3IP/HOP2 mutation that 

370, 972–974

Pu, D. *et al.* (2016) Association analysis between HFM1 variation and primary ovarian insufficiency 

Carlosama, C. *et al.* (2017) A homozygous donor splice-site mutation in the meiotic gene MSH4 
causes primary ovarian insufficiency. *Hum. Mol. Genet.* 26, 3161–3166

1452–1457

Diseases. *Hum. Mutat.* 38, 193–203


Murray, J.E. et al. (2014) Extreme growth failure is a common presentation of ligase IV deficiency. Hum. Mutat. 35, 76–85


Fu, C. et al. (2016) Primary Ovarian Insufficiency Induced by Fanconi Anemia E Mutation in a Mouse Model. PloS One 11, e0144285

Fouquet, B. et al. (2017) A homozygous FANCM mutation underlies a familial case of non-syndromic primary ovarian insufficiency. eLife 6, e30490

Michl, J. et al. (2016) Interplay between Fanconi anemia and homologous recombination pathways in genome integrity. EMBO J. 35, 909–923


Soldà, G. et al. (2016) First independent replication of the involvement of LARS2 in Perrault syndrome by whole-exome sequencing of an Italian family. J. Hum. Genet. 61, 295–300


Hochberg, I. et al. (2017) A homozygous variant in mitochondrial RNase P subunit PRORP is associated with Perrault syndrome characterized by hearing loss and primary ovarian insufficiency. bioRxiv DOI: 10.1101/168252


Lakshmanan, R. et al. (2017) Redefining the phenotype of ALSP and AARS2 mutation-related leukodystrophy. Neurol. Genet. 3, e135


Kasippillai, T. et al. (2013) Mutations in eIF4ENIF1 are associated with primary ovarian insufficiency. J. Clin. Endocrinol. Metab. 98, E1534-1539

Bouilly, J. et al. (2011) Novel NOBOX loss-of-function mutations account for 6.2% of cases in a large primary ovarian insufficiency cohort. Hum. Mutat. 32, 1108–1113


Figure 1

**HUMAN**
- PGC
- Oogonia
- Meiotic Follicles

**MOUSE**
- PGC
- Oogonia
- Meiotic Follicles

**PGC specification**
- migration colonization

**Meiotic entry**
- leptotene
- zygotene
- pachytene
- diplotene

**Meiotic arrest**

**nest breakdown**
- follicle formation recruitment

**MITOTIC**
- POU5F1/TFAP2C
- DAZL/DDX4
- STRA8/SYCP3
- NOBOX/TP63

**MEIOTIC**
- STRA8 ↔ RA
- CYP26B1
- FOXO3
- PI3K
- AKT
- PTEN
- KITL

BMPs → PRDM1 PRDM14

**MOUSE**
- migration colonization

**HUMAN**
- migration colonization
Cell attachment and migration: **ANTXR1**

Nuclear functions: **NUP107**

DNA damage, repair, replication: **NBN, RECQL4, XRCC4, CSB-PGDBD3, SPIDR**

Translational and post-translational regulations: **EIF2B, RCBTB1, EIF4ENIF1**

Mitochondrial function: **AARS2, HARS2, LARS2, MT-ATP6/8, C10ORF2, KIAA0391, ERAL1, POLG**

Peroxisomal function: **HSD17B4**

Metabolic defect: **PMM2**
Crossover

Double strand breaks
PRDM9, SPO11, TOPVIBL, MEI1, MEI4, REC114, IOH1, HORMAD1

Homology search
RAD51, DMC1, RPA, MEIOB, SPATA22, BRCA2, RAD54, MND1, PSMC3IP, RAD52, FMR1, BRCA1, ATR, ATM

Stabilisation
MCM8, MCM9, RNF212, HEI10, MSH4, MSH5, HFM1, TEX11

MLH1, MLH3, EXO1

Non crossover

Crossover

Synaptonemal complex
SYCE1, SYCP1, SIX6OS1, SYCE2, TEX12
SYCP3, SYCP2

central element lateral elements

BLM, TOP3, RMI1

FANCM

cohesins
STAG3, RAD21L, REC8, SMC1B, SMC3

SYCE1, SYCP1, SIX6OS1, SYCE2, TEX12

Figure 3
Figure 4

**GRANULOSA CELL OF SECONDARY FOLLICLE**

- G-actin
- F-actin
- POLYMERISATION

**HIPPO SIGNALING OFF**

- YAP/TAZ
- TEAD 1/2/3/4
- NUCLEUS
- CCN, BIRC6

- DEGRADATION OF PHOSPHO-YAP/TAZ

**OOCYTE OF DORMANT PRIMORDIAL FOLLICLE**

- PTEN
- PI3K
- AKT
- PDK1
- FOXO3

**IVA DRUG TREATMENT**

- PTEN inhibition
- AKT stimulation

**OPTIONAL:**

- CRYOPRESERVATION OF OVARIAN TISSUE

**OVARIECTOMY OF POI PATIENT**

- EMBRYO TRANSFER

**EMBRYO CULTURE**

- ICSI or IVF
- MII OOCYTE

**AFH TREATMENT OF POI PATIENT**

- OOCYTE RETRIVAL

**ACTIVATION VIA OOCYTE**

- Activated RTKs
- MIGRATION TO NUCLEUS

**OPTIONAL:**

- PTEN INHIBITORS CPVhopic

**PROMOTION THROUGH GRANULOSA CELL PROLIFERATION FOLLOWED BY AKT STIMULATION**

**GRANULOSA CELL PROLIFERATION**
POI DIAGNOSIS
PA or SA or spaniomenorrhea > 4 months, two FSH values >25 U/L, low E2, normal PRL, normal TSH

Personal history, physical examination, ovarian reserve: US: ovary and AFC + AMH
Familial study: age menopause, 46XY sex reversal, others

Karyotype, FMR1

Abnormal karyotype, Xfra syndrome

Unexplained POI

Isolated POI

AMH, US: ovaries, AFC +
AMH, US: ovaries, AFC -

Hormonal treatment

+/- aCGH NGS

Defects in genes involved in follicular growth and function: possible ovarian reserve
Defects in genes involved in ovarian differentiation, oogenesis, establishment of the follicular pool

Syndromic POI

+ familial DSD
+ symphalangism
+ goiter, vitiligo auto-antibodies
+ candidiasis, Addison
+ ptosis, epicanthus: BPES
+ metabolic syndrome, galactosemia
+ neurosensory symptoms
+ cardiomyopathy
+ brachydactyly, short stature, high PTH/TSH, obesity
+ cancer, leukemia, small size, hypothyroidism, chromosome instability

 +/- aCGH, NGS specific gene(s)

+ deafness Perrault syndrome
+ VWM syndrome ovarioleukodystrophy
+ cerebellar syndrome, ataxia
+ ataxia telangectasia
+ ophtalmoplegia, tremor
+ GAPO syndrome
+ retinal dystrophy, intelectual disability

- Genetic and therapeutic counseling, patient and relatives - multidisciplinary team-

Fertility preservation IVA in the future
Egg donation

Specific treatment of associated symptoms